Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses compared with adjuvant treatment 1 ; however, optimal regimens have not been defined. Here we report results from a randomized phase 2 study of neoadjuvant nivolumab versus combined ipilimumab with nivolumab in 23 patients with high-risk resectable melanoma (NCT02519322). RECIST overall response rates (ORR), pathologic complete response rates (pCR), treatment-related adverse events (trAEs) and immune correlates of response were assessed. Treatment with combined ipilimumab and nivolumab yielded high response rates (RECIST ORR 73%, pCR 45%) but substantial toxicity (73% grade 3 trAEs), whereas treatment with nivolumab monotherapy yielded modest responses (ORR 25%, pCR 25%) and low toxicity (8% grade 3 trAEs). Immune correlates of response were identified, demonstrating higher lymphoid infiltrates in responders to both therapies and a more clonal and diverse T cell infiltrate in responders to nivolumab monotherapy. These results describe the feasibility of neoadjuvant immune checkpoint blockade in melanoma and emphasize the need for additional studies to optimize treatment regimens and to validate putative biomarkers.
Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses compared with adjuvant treatment 1 ; however, optimal regimens have not been defined. Here we report results from a randomized phase 2 study of neoadjuvant nivolumab versus combined ipilimumab with nivolumab in 23 patients with high-risk resectable melanoma (NCT02519322). RECIST overall response rates (ORR), pathologic complete response rates (pCR), treatment-related adverse events (trAEs) and immune correlates of response were assessed. Treatment with combined ipilimumab and nivolumab yielded high response rates (RECIST ORR 73%, pCR 45%) but substantial toxicity (73% grade 3 trAEs), whereas treatment with nivolumab monotherapy yielded modest responses (ORR 25%, pCR 25%) and low toxicity (8% grade 3 trAEs). Immune correlates of response were identified, demonstrating higher lymphoid infiltrates in responders to both therapies and a more clonal and diverse T cell infiltrate in responders to nivolumab monotherapy. These results describe the feasibility of neoadjuvant immune checkpoint blockade in melanoma and emphasize the need for additional studies to optimize treatment regimens and to validate putative biomarkers.
Clinical outcomes for patients with stage III melanoma have historically been poor 2 ; however recent advances in treatment with adjuvant immune checkpoint blockade (ICB) have demonstrated survival benefits, substantiating the Food and Drug Administration (FDA) approval of single-agent ipilimumab (CTLA-4 blockade) 3 and nivolumab (PD-1 blockade) 4 treatments in patients with highrisk resected disease, and with recent data also showing benefits with adjuvant pembrolizumab 5 . Treatment with combined CTLA-4 and PD-1 blockade is also being studied in the adjuvant setting (NCT03068455 and NCT03241186), although toxicity with this regimen can be considerable 6, 7 .
The current standard of care for patients with clinical stage III melanoma is upfront surgery with adjuvant therapy; however, we have recently demonstrated that treatment with neoadjuvant and adjuvant targeted therapy (dabrafenib and trametinib) is associated with high pCR rates and improved outcomes over standard of care upfront surgery 8 . Preclinical studies suggest that neoadjuvant administration of ICB is associated with improved survival and enhanced antitumor immune responses compared to the same therapy administered in the adjuvant setting 1 . Treatment with ICB has not been well-studied in the neoadjuvant setting in melanoma, although its feasibility has been demonstrated in non-small-cell lung cancer 9 . On the basis of these results and the described preclinical studies, we conducted a randomized, noncomparative phase 2 trial of neoadjuvant nivolumab monotherapy (3 mg kg −1 intravenous administration; every 14 d for up to four doses) and combined ipilimumab with nivolumab (ipilimumab 3 mg kg −1 and nivolumab 1 mg kg −1 intravenous administration; every 21 d for up to three doses) to define clinical responses (radiographic, pathologic and survival rates) and immunologic biomarkers of response in patients with surgically resectable clinical stage III or oligometastatic stage IV disease (NCT02519322) (Fig. 1) .
A total of 30 patients were consented and assessed for eligibility, of whom 23 were enrolled in the trial ( Supplementary Fig. 1 ). All patients were required to provide written informed consent prior to treatment, and this trial adhered to all relevant ethical considerations. In total, 12 patients were randomized to nivolumab monotherapy and 11 patients were randomized to combined therapy with ipilimumab and nivolumab. The median (and range) of follow-up Letters NATuRE MEdICINE was 15.0 months (5.8-22.6) in the nivolumab monotherapy arm and 15.6 months (5. 8-24.4) in the combination therapy arm; no significant differences in baseline patient characteristics were observed between arms (Supplementary Table 1 ). The majority of patients had clinical stage IIIB or IIIC disease 10 , with most having superficial spreading and nodular melanoma, whereas no patients had mucosal or acral subtypes in this cohort. Of note, three of the patients in the combination therapy arm previously received adjuvant interferon or peginterferon, and one of the patients in the nivolumab monotherapy arm had previously received neoadjuvant dabrafenib and trametinib followed by surgery and then adjuvant radiation and biochemotherapy. All other patients were either treatment naive or had previously only received surgical resection for primary melanoma.
Of note, a total of 40 patients were planned for accrual; however, the trial was stopped early by the Data Safety Monitoring Board on the basis of an early observation of disease progression, preventing surgical resection during neoadjuvant nivolumab treatment (17%; 2 out of 12 patients) and high rates of grade 3 trAEs during neoadjuvant combination treatment (73%; 8 out of 11 patients), especially in light of more recent trial designs that studied alternative dosing regimens of combined ipilimumab with nivolumab that were better tolerated.
The RECIST ORR was 25% (3 out of 12 patients) with nivolumab monotherapy ( Fig. 2a and Supplementary Fig. 2a ) and 73% (8 out of 11 patients) with combined ipilimumab and nivolumab therapy ( Fig. 2b and Supplementary Fig. 2b ), while pCR rates were 25% (3 out of 12 patients) and 45% (5 out of 11 patients), respectively. A representative response is shown ( Fig. 2c ). Two patients with progressive disease while receiving nivolumab monotherapy were unable to receive definitive surgical resection owing to the development of synchronous metastatic disease as well as local progression. Compared to nivolumab alone, the combination of ipilimumab and nivolumab yielded improved radiologic and pathologic outcomes as analysed by Fisher's exact test (P = 0.039 and P = 0.40, respectively).
Treatment with combination therapy was associated with improved progression-free survival (PFS), relapse-free survival (RFS), distant metastasis-free survival (DMFS) and overall survival over treatment with nivolumab alone, although this did not achieve statistical significance, likely owing to the small sample size due to early closure of the trial ( Fig. 3 and Supplementary Fig. 3 ). Notably, with a median follow-up of 15.6 months (range 5.8-24.4), 11 out of 11 of the patients receiving dual checkpoint blockade are still alive. Improved RFS, DMFS and overall survival were observed in patients who achieved a pCR following neoadjuvant therapy versus those who did not ( Supplementary Fig. 4 ). This was also observed for patients who achieved a RECIST response (complete or partial response) versus those who did not (stable or progressive disease) ( Supplementary Fig. 5 ). However, these results did not reach statistical significance, likely owing to the limited sample size. Importantly, toxicity rates differed significantly between treatment arms during neoadjuvant treatment, with grade 3 trAEs reported in 8% (1 out of 12 patients) of patients treated with monotherapy and in 73% (8 out of 11 patients) of patients treated with combination therapy (Supplementary Table 2 ); no grade 4 or 5 trAEs were observed. The only grade 3 trAE for nivolumab-treated patients was tumor-related pain. By contrast, grade 3 trAEs for combination therapy-treated patients included transaminitis (27%), colitis (18%), hyperthyroidism (9%), pneumonia (18%), arthralgias (9%), myositis and/or myalgias (9%), electrolyte abnormalities (hypokalemia 9%, hyponatremia 18%), hyperglycemia (9%), fall (9%) and sinus tachycardia (9%). Dose delays were required in 64% of patients (7 out of 11 patients) receiving combined ipilimumab and nivolumab therapy. None of the patients receiving nivolumab monotherapy required dose delays. During the postoperative and adjuvant periods ( Supplementary Table 3) , grade 3 or more severe trAEs were observed in an additional two patients in the nivolumab-treated arm (grade 3 colitis in one patient, grade 4 diabetic ketoacidosis in one patient) and an additional one patient in the combination-treated arm (hypophysitis).
Responders demonstrated a trend towards a higher total mutational burden compared to nonresponders, although responses were seen even in patients with a low mutational burden ( Fig. 4a ). Immune profiling via immunohistochemistry (IHC) performed on baseline and early on-treatment tumor samples demonstrated higher CD8 + T cell infiltrate, tumor cell PD-L1 expression, and expression of lymphoid markers (granzyme B, CD4, FoxP3, CD20 and PD-1) in responders compared to nonresponders ( Fig. 4b-d and Supplementary Fig. 6 ). Early on-treatment biopsies showed a stronger predictive signal for most of these markers compared to baseline, consistent with previously published literature 11 
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NATuRE MEdICINE expression of CD45RO, β 2-microglobulin, T cell markers (CD3 and CD8) and B cell markers (CD19 and CD20). In addition, cell proliferation (assessed by Ki-67) within CD45 + cells was higher in responders compared to nonresponders ( Fig. 4e , Supplementary Fig. 7 and Supplementary Tables 4-9) .
Sequencing of T cell receptors demonstrated higher clonality in tumors of responders (at pre-and on-treatment time points) similar to that described in previously published studies 12 (Fig. 4f ). Of note, the increased clonality in on-treatment samples was predominantly observed in responders to nivolumab monotherapy, while patients responding to combined ipilimumab and nivolumab displayed a more heterogeneous pattern of clonality. T cell diversity was similarly higher in responders to nivolumab monotherapy, suggesting that responders to nivolumab monotherapy have a more diverse T cell repertoire with a subset of tumor-reactive clones accounting for the high clonality ( Supplementary Fig. 8 ). To further investigate longitudinal changes in T cell repertoire, we assessed T cell repertoire dynamics using differential abundance analysis and found greater treatment-induced clonal expansion within the tumors of nivolumab responders compared to nonresponders ( Fig. 4g,h ). Furthermore, nivolumab responders exhibited a greater frequency of pre-existing T cell clones at baseline that were either preserved or further expanded with treatment ( Fig. 4i ). By contrast, the dynamics of the intratumoral T cell repertoire in patients treated with the combination of ipilimumab and nivolumab demonstrated greater variability under treatment ( Fig. 4g ). Analysis of the T cell repertoire in peripheral blood revealed significant expansion of tumor-resident T cell clones from baseline to early on-treatment in the setting of treatment with combined ipilimumab and nivolumab compared to nivolumab monotherapy ( Supplementary Fig. 8 ). However, this was not associated with differences in response ( Supplementary Fig.  8 ). Parallel analyses of the effect of total mutational burden, IHC parameters and T cell repertoires using pCR as an outcome demonstrated similar findings (Supplementary Figs. 6, 7, 9 and 10) .
We describe a randomized neoadjuvant trial of single-or dualagent ICB in patients with resectable clinical stage III or oligometastatic stage IV melanoma. Treatment with neoadjuvant nivolumab was well-tolerated and was associated with reasonable response rates (ORR and pCR); however, the frequency of marked disease progression during neoadjuvant nivolumab monotherapy that precluded standard of care surgery underscored clinical concerns with this approach. By contrast, neoadjuvant therapy with combined ipilimumab and nivolumab resulted in higher response and pCR rates, but with higher toxicities. This was achieved despite the fact that 64% of patients (7 out of 11 patients) received only two of the planned three neoadjuvant doses. It is notable that 11 out of 11 patients receiving dual immune checkpoint blockade remain alive after a median of 15.6 months (range 5.8-24.4), which is a higher proportion surviving at this time point than expected compared with historical controls for this high-risk patient population 5, 13, 14 .
The promising activity seen in the combination arm supports the rationale for expanded evaluation of combination ICB agents in the neoadjuvant setting.
Compared to RECIST responses seen in the metastatic setting with the medication doses and schedules used in this trial 6 , in this neoadjuvant cohort we observed higher response rates (73% versus . Two of the patients progressed beyond resectability and did not receive surgical resection. b, Combination therapy with ipilimumab and nivolumab (n = 11) yielded improved outcomes compared to nivolumab, 73% RECIST ORR (risk difference 48%, 95% confidence interval 12-84%, P = 0.039) and 45% pCR rate (risk difference 20%, 95% confidence interval 18-59%, P = 0.40) using two-sided Fisher's exact test. c, Only one patient on the trial who had a pCR also had a radiographic complete response (CR), with the other pathologic responders having partial responses.
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approximately 60%) and rates of grade 3 or more severe trAEs (73% versus approximately 60%) with combination therapy, and lower response rates (25% versus around 40%) and rates of grade 3 or more severe trAEs (8% versus about 20%) with nivolumab monotherapy. Given the relatively small size of this study, however, it is difficult to draw conclusions on whether there is a true difference in efficacy and toxicity of ICB between resectable and unresectable disease. Notably, treatments have been adjusted since our trial was designed to optimize dosing regimens and schedules for these agents. For example, shorter neoadjuvant treatment regimens have been explored incorporating anti-PD-1 monotherapy in melanoma and lung cancer with success 9, 15 . In addition to this, alternative dosing strategies for combined CTLA-4 and PD-1 blockade (such as ipilimumab 1 mg kg −1 and nivolumab 3 mg kg −1 or less frequent dosing) are also being explored to preserve efficacy while limiting toxicity (NCT02977052, NCT03068455, NCT03241186, NCT03158129 and NCT01454102). Furthermore, new agents with potentially lower toxicity than CTLA-4 blockade are now being tested in the neoadjuvant setting for patients with resectable metastatic melanoma, including in our amended trial-in which treatment with nivolumab will be combined with relatlimab-a monoclonal antibody blocking lymphocyte-activation gene 3 (LAG-3), an immune checkpoint molecule frequently upregulated in cancer.
Detailed immunologic correlative studies recapitulated several known immune biomarkers of response to ICB in the metastatic melanoma setting, with early on-treatment biopsies showing higher lymphoid immune infiltrates and a more clonal T cell repertoire in responders compared to nonresponders 11, 12 . Higher clonality at baseline is especially prominent in responders to nivolumab monotherapy, with further expansion of the pre-existing high-frequency clones with treatment. These data highlight the importance of and perhaps need for a tumor-educated (but inhibited) T cell repertoire in shaping the response to anti-PD-1 monotherapy and are consistent with prior reports 16, 17 . However, responses to treatment with combined ipilimumab and nivolumab therapy seem to be less dependent on a preexisting intratumoral T cell repertoire, and this treatment is associated with an increase in tumor-resident T cell clones in the periphery.
This study has several limitations, including a relatively small sample size, which is a result of early trial closure. However, despite this limitation, the data do provide preliminary evidence regarding efficacy and toxicity of anti-PD-1 monotherapy and combined anti-CTLA-4 and anti-PD-1 therapy in patients with resectable high-risk metastatic melanoma. The data suggest that although neoadjuvant administration of single agent anti-PD-1 is safe, disease progression within the neoadjuvant period can occur in a subset of patients. Additionally, although combination anti-PD-1 and anti-CTLA-4 is more effective . Median survival end points have not been reached. Combination ipilimumab and nivolumab resulted in improved survival outcomes compared to nivolumab monotherapy, although this did not reach significance. The numbers under the graphs indicate the number of patients exposed to each medication and at risk for the event at each time point. For PFS, survival rates of 82% (95% confidence interval 45-95%) at 17.2 months with ipilimumab and nivolumab treatment versus 58% (27-80%) at 22.6 months with nivolumab treatment, P = 0.19. For DMFS, rates of 91% (51-99%) at 17.2 months with ipilimumab and nivolumab treatment versus 67% (34-86%) at 22.6 months with nivolumab treatment, P = 0.17. For overall survival, rates of 100% (100-100%) at 24.4 months with ipilimumab and nivolumab treatment versus 76% (31-94%) at 22.6 months with nivolumab treatment, P = 0.18. Ipi + Nivo Nivo n/a n/a n/a n/a n/a Longitudinal tumor biopsies were obtained at baseline and early on-treatment in patients on neoadjuvant ICB therapy. The tumor molecular and immune microenvironment was compared between nonresponders (NR) and responders (R), with responders defined as patients achieving a complete or partial response by RECIST 1.1. a, The total mutational burden, defined as the sum of nonsynonymous exonic mutations, is shown (n = 8 nonresponders and 7 responders). b,c, Quantification by IHC of CD8 cell count density (n = 11 nonresponders and 10 responders at baseline, n = 11 nonresponders and 9 responders on-treatment) and PD-L1 H score (28-8 clone) (n = 11 nonresponders and 10 responders at baseline, n = 11 nonresponders and 9 responders on-treatment). NS, not significant. d, Supervised hierarchical clustering summarizes expression of additional lymphoid markers (granzyme B (GzmB), CD4, FoxP3, CD20 and PD-1) using standard IHC, with blue indicating lower count density and red higher count density (or H score for PD-L1). NA, not available. e, Volcano plots of two-sided pairwise Mann-Whitney U-test comparisons of the expression of multiplex IHC markers between responders and nonresponders in baseline (green) and on-treatment (red) samples in the combined treatment arms (n = 11 nonresponders and 11 responders at baseline, n = 10 nonresponders and 6 responders on-treatment). Expression of immune markers was assessed on CD45 + cells and quantified as expression per area of assayed tissue. MS4A1 is also known as CD20. f, T cell clonality scores between responders and nonresponders at baseline (left, n = 10 nonresponders and 9 responders) and on-treatment (right, n = 10 nonresponders and 9 responders). g, Analysis of change in T cell repertoire was performed using differential abundance analysis. Clones that significantly increase (red) or decrease (blue) in frequency from baseline (closed circles) to on-treatment (open circles) are shown for the whole clinical trial cohort. h,i, Change in T cell repertoire was assessed for the number of significantly expanded clonotypes (n = 6 nonresponders and 3 responders for nivolumab-treated patients, n = 3 nonresponders and 6 responders for combination therapy-treated patients) and Morisita Overlap index (n = 6 nonresponders and 3 responders for nivolumab-treated patients, n = 3 nonresponders and 6 responders for combination therapy-treated patients). In a-c, f, h and i, bar heights indicate median values, and interquartile ranges are presented in addition to individual data points. Comparisons were made using two-sided Mann-Whitney U-tests.
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in terms of response rates and the ability to produce pCR, this efficacy comes at the expense of pronounced toxicity. Currently, although there is a trend towards improved clinical survival outcomes for patients treated with combination therapy, the data are too premature to be conclusive, and longer term follow-up is essential. Another limitation in study interpretation is regarding the comparison of the two treatment arms. Exploratory analyses were performed between treatment arms to gain insight into potential differences in efficacy and toxicity; as the trial was designed with two noncomparative arms, these results need to therefore be interpreted with caution. Although findings from these studies are provocative, additional studies in larger cohorts will be needed to validate these findings and to further optimize therapeutic approaches.
Of note, our original trial design included patients with American Joint Committee on Cancer (AJCC) seventh edition stage IIIB, IIIC and oligometastatic stage IV disease. The inclusion of patients with oligometastatic stage IV disease renders this study population relatively heterogeneous and thus decreases the generalizability of this data to a stage III population. In future trials, limiting these treatments to more defined patient cohorts, such as AJCC eigth edition stage IIIB, IIIC, IIID melanoma only, may be a more reasonable strategy. Additionally, these data are limited to patients with cutaneous or unknown primary melanoma, as no cases of mucosal or acral subtypes were included in this trial. As such, it remains unclear whether our findings apply to patients with these melanoma subtypes.
Together, these results provide critical data on the performance of two 8-9 week neoadjuvant ICB regimens that are commonly used in unresectable melanoma-nivolumab 3 mg kg −1 every 2 weeks and ipilimumab 3 mg kg −1 with nivolumab 1 mg kg −1 every 3 weeks-in patients with resectable clinical stage III and oligometastatic stage IV melanoma and suggest that treatment with combined ipilimumab and nivolumab is associated with improved responses but also considerable toxicity. Further studies are needed to optimize these regimens and determine long-term benefits as well as to better understand the mechanistic underpinnings of therapeutic response and resistance.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41591-018-0197-1.
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Methods
Patients. Eligible patients were at least 18 years of age with histologically proven clinical stage III or oligometastatic stage IV cutaneous, mucosal or acral melanoma according to the AJCC seventh edition 10 . Clinical stage III disease was defined as at least one lymph node metastasis measuring 1.5 cm in short axis or at least one 1.0-cm in-transit metastasis, as per RECIST 1.1 criteria 18 . Patients with oligometastatic stage IV melanoma were eligible if there were < 4 sites of metastases with no involvement of the bones and brain. Only patients with surgically resectable disease, as determined by a multidisciplinary consensus review, were eligible. All patients had Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with normal organ and bone marrow function. Key exclusion criteria included prior exposure to ICB agents, use of anticoagulants, a concurrent medical condition that required chronic corticosteroids or other immunosuppressive medication, or active concurrent second cancer. A complete list of inclusion and exclusion criteria is provided in the protocol provided in the Supplementary Note.
Trial design and treatments. In this single-institution, investigator-initiated phase 2 randomized noncomparative study, patients were randomized to receive four doses of nivolumab (arm A) or three doses of the combination of ipilimumab and nivolumab (arm B) administered in a neoadjuvant manner. Patients were stratified based on stage (IIIB/IIIC/M1A versus M1B/M1C) and PD-L1 status (less than or greater than 1% tumor cells positive for membranous staining; clone 28-8), and then randomized in a 1:1 ratio between arms A and B. Patients in arm A received up to four doses of nivolumab 3 mg kg −1 intravenously on weeks 1, 3, 5 and 7. Patients in arm B received up to three doses of nivolumab 1 mg kg −1 and ipilimumab 3 mg kg −1 on weeks 1, 4 and 7. Patients were closely monitored for local disease progression during neoadjuvant therapy. Following neoadjuvant treatment, patients underwent restaging with assessment of radiographic responses (via RECIST) and proceeded to surgery if no contraindication was present, such as development of unresectable distant metastases. All patients undergoing surgery were offered nivolumab 3 mg kg −1 intravenously every 2 weeks for 13 doses in the adjuvant setting as long as they did not require adjuvant radiation and did not experience unacceptable toxicities during neoadjuvant therapy ( Supplementary Fig. 1 ).
Primary and secondary end points. The primary end point of this study was assessment of pathologic response in each arm at the time of surgical resection. Secondary end points included: assessment of ORR by RECIST 1.1 to neoadjuvant therapy; PFS, defined as the time from study randomization to development of radiographic progression before surgery, disease recurrence after surgical resection or death from any cause; RFS, defined as the time from surgery to disease recurrence or death from any cause; DMFS, defined as the time from study randomization to development of distant metastases or death from any cause; overall survival, defined as the time from randomization to death from any cause; and safety. Exploratory analyses were undertaken to identify immunologic and genomic predictors of therapeutic response and to gain mechanistic insight on treatment efficacy.
Pathologic and clinical assessments.
Patients who received per-protocol neoadjuvant treatment and underwent surgery were evaluable for the primary end point of pathologic response. Surgical samples were analyzed by dermatopathologists for pCR, defined as the absence of any viable malignant cells on H&E-stained slides and confirmatory SOX-10 IHC staining of representative sections in ambiguous cases, as has been advocated for other systems 8, 19 .
Disease assessments included clinical examinations and imaging studies (positron-emission tomography-computed tomography or computed tomography of the chest, abdomen and pelvis with contrast; magnetic resonance imaging or computed tomography of the brain) at baseline, at completion of neoadjuvant treatment (around week 9), and every 12 weeks after surgery for up to 2 years. Radiologic assessment immediately after neoadjuvant therapy was performed according to RECIST 1.1 criteria to classify best response to therapy as complete or partial response, stable or progressive disease. ORR was defined as complete plus partial response rates. All randomized patients were eligible for evaluation of PFS. Patients who underwent surgery were eligible for evaluation of RFS. All randomized patients were evaluable for DMFS and for overall survival. For survival comparisons of responders versus nonresponders (by either pathologic response or RECIST), all survival end points were defined from the time of surgery.
Adverse events and laboratory values were assessed at screening, baseline and prior to each neoadjuvant and adjuvant dose, and were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, v.4.0 20 .
Trial oversight. This trial was approved by the MD Anderson Cancer Center
Institutional Review Board. The trial was conducted in accordance with the ethical principles of the Declaration of Helsinki and with adherence to the Good Clinical Practice guidelines, as defined by the International Conference on Harmonization. This protocol was conducted with compliance with all relevant ethical regulations. Written informed consent was obtained from all participants. The MD Anderson Data Safety Monitoring Board reviewed the data at 12-month increments. The drug manufacturer (Bristol-Myers Squibb) funded the trial and supplied the agents but had no role in the design or execution of the trial, the collection or analysis of the data or the preparation of the manuscript.
Biospecimen collection. Blood and tumor samples were collected at several timepoints for correlative studies including baseline, on-treatment (weeks 3 and 5 for arm A, weeks 4 and 7 for arm B) and at surgical resection. Details on timing of on-treatment sample collection in the analyses included in this study are shown in Supplementary Table 10 . Blood collection was continued every 12 weeks in the adjuvant setting. Tumor samples were obtained as core, punch or excisional biopsies performed by the treating clinicians or an interventional radiologist. Samples were immediately formalin-fixed and paraffin-embedded (FFPE) or snapfrozen following tissue collection.
Singlet IHC. H&E and IHC staining were performed on FFPE tumor tissue sections. The tumor tissues were fixed in 10% formalin, embedded in paraffin, and sectioned into 4-μ m sections used for histopathological study. Sections were stained with mouse or rabbit anti-human monoclonal antibodies against CD4 (Novocastra, CD4-368-L-A, 1:80), CD8 (Thermo Scientific, MS-457-S, 1:25), FoxP3 (BioLegend, 320102, 1:50), granzyme B (Leica Microsystems, PA0291, 1:1), CD20 (Dako, M0755, 1:1,400), PD-1 (Abcam, ab137132, 1:250) and PD-L1 (Cell Signaling Technologies, 13684, 1:100). All sections were counterstained with hematoxylin, dehydrated and mounted. Sections were processed with peroxidaseconjugated avidin/biotin and 3′ -3-diaminobenzidine (DAB) substrate (Leica Microsystems), and slides were scanned and digitalized using the scanscope system from Scanscope XT (Aperio/Leica Technologies).
Quantitative analysis of IHC staining was conducted using the image analysis software ImageScope-Aperio/Leica. Five random areas (1 mm 2 each) were selected using a customized algorithm for each marker in order to determine the number of positive cells per high-powered field. The data are expressed as a percentage score (number of positive cells/total number of cells) or density (total number of positive cells per mm 2 area). IHC staining was interpreted in conjunction with H&E-stained sections.
Multiplex IHC. Multiplex IHC was performed using Digital Spatial Profiling (NanoString). An automated setup capable of imaging and sample collection was developed by modifying a standard microscope and controlling it with Metamorph (Molecular Devices) and custom-built software. For protein detection, a multiplexed cocktail of primary antibodies, each with a unique, ultraviolet-light photocleavable indexing oligo, and/or 1-3 fluorescent markers (antibodies and/ or DNA dyes) was applied to a slide-mounted FFPE tissue section. The tissue slide was placed on the stage of an inverted microscope (Nikon, Ti-E). A custom gasket was then clamped onto the slide, allowing the tissue to be submerged in 1.5 ml of buffer solution (tris-buffered saline with Tween 20 (TBST), protein assay; 2× SSC + 0.1% Tween 20, RNA assay). The gasket clamp design allows the buffer to be accessed from above by a microcapillary tip (100 µ m inner diameter). The microcapillary tip is connected to a syringe pump (Cavro XCalibur) primed with buffer solution, allowing for accurate aspiration of small volumes (< 2.5 µ l). Additionally, the tip is mounted to a separate, vertically aligned z-stage (ASI LS-50), which provides submicron tip-position accuracy over the tissue. Under the microscope, wide-field fluorescence imaging was performed with epi-illumination from a visible-LED-light engine (Lumencor, SOLA). The tissue area of interest was then located using fluorescence imaging with a 4× objective (Nikon). This was followed by 20× (Nikon, ELWD) fluorescence scanning. Each 20× image corresponds to 665 µ m × 665 µ m of tissue area with a CMOS camera (Hamamatsu, Flash 4.0). The 20× images were assembled to yield a high-resolution image of the tissue area of interest. The specific regions of interest (ROIs) for molecular profiling were then selected on the basis of the fluorescence information and sequentially processed by the microscope automation.
The steps performed for each ROI by the microscope automation were as follows. First, the microcapillary tip was washed by dispensing clean buffer out of the capillary and into a wash station. Next, the tissue slide was washed by exchanging the buffer solution on the slide via the inlet and outlet wash ports on the gasket clamp. The microcapillary tip was then moved into position 50 µ m above the ROI. The local area of tissue around the ROI was washed by dispensing 100 µ l of buffer solution from the microcapillary. Then, the ROI was selectively illuminated with ultraviolet light to release the indexing oligos by coupling ultraviolet LED light with a digital mirror device (DMD) module (Andor, Mosaics3). Ultraviolet LED light was collimated to be reflected from the DMD surface into the microscope objective, and focused at the sample tissue (365 nm and ~125 mW cm −2 or 385 nm and ~800 mW cm −2 ; 6-s exposure for the protein assay). Each micromirror unit in the DMD corresponds to an approximately 1-µ m 2 area of sample and reflects the ultraviolet light in a controlled pattern based on the ROI selection in the image. Following each ultraviolet-light illumination cycle, the eluent was collected from the local region through microcapillary aspiration and transferred to an individual well of a microtiter plate. Once all ROIs were processed, pools of released indexing oligos were hybridized to NanoString optical barcodes for digital counting and subsequently analyzed with an nCounter Analysis System using the protocol below.
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Sample preparation for protein profiling and IHC. Each selected primary antibody was coupled to a unique 70-bp indexing oligo (NanoString, custom conjugation service). All assays were performed on 5-µ m FFPE sections mounted onto charged slides. Deparaffinization and rehydration of tissue was performed by incubating slides in three washes of CitriSolv (Decon Labs, Inc., 1601) for 5 min each, two washes of 100% ethanol for 10 min each, two washes of 95% ethanol for 10 min each and two washes of dH 2 O for 5 min each. Slides were then placed in a plastic Coplin jar containing 1× citrate buffer pH 6.0 (Sigma-Aldrich, C9999) and covered with a lid. The Coplin jar was placed into a pressure cooker (BioSB, BSB7008) and run on high pressure and temperature for 15 min. The Coplin jar was removed from the pressure cooker and cooled at room temperature for 25 min. Slides were washed with five changes of 1× TBST (Cell Signaling Technology, 9997) for 2 min each. Excess TBST was removed from the slide, and a hydrophobic barrier was drawn around each tissue section with a hydrophobic pen (Vector Laboratories, H-4000). Slides were then incubated with blocking buffer (1× TBST, 5% goat serum (Sigma-Aldrich, G9023-5ML), 0.1 mg ml −1 salmon sperm DNA (Sigma-Aldrich, D7656) and 10 mg ml −1 dextran sulfate (Sigma-Aldrich, 67578-5 G)) for 1 h. Slides were washed with three changes of 1× TBST for 2 min each. Primary antibodies were diluted in antibody diluent (Signal Stain Antibody Diluent (Cell Signaling Technology, 8112), 0.1 mg ml −1 salmon sperm DNA and 10 mg ml −1 dextran sulfate). Tissue sections were then covered with diluted primary antibody solution. Slides were incubated at 4 °C in a humidity chamber overnight. Primary antibodies were aspirated from the slides and slides were washed with three changes of 1× TBST for 10 min each. DNA was counterstained with 100 nM SYTO 83 (ThermoFisher, S11364) in 1× TBST for 15 min. Excess SYTO 83 was removed with five washes of TBST, and each slide was processed in an automated manner on the instrument described above.
Custom masking. For each ROI, 20× stacked TIFF images of fluorescent CD45 (Alexa Fluor 647) and DNA (SYTO 83) were processed with ImageJ to create custom masks. Each stacked TIFF was split into two images, and the CD45 image was manually thresholded to select positive cells. The thresholded CD45 image was converted to mask, image inverted, dilated, holes filled, inverted LUT and then image inverted to create the final CD45 mask (first mask).
Hybridization assay set-up. Hybridization of cleaved indexing oligos to fluorescent barcodes was performed using the nCounter Protein TagSet reagents (NanoString, 120100002). Indexing oligos were denatured at 95 °C for 3-5 min and placed on ice for 2 min. A mastermix was created by adding 70 μ l of hybridization buffer to the Protein TagSet tube. A 7-μ l aliquot of mastermix was added to each of 12 hybridization tubes. Depending on the experiment, 2-8 µ l of the denatured protein sample was added to each tube. Hybridizations were performed at 65 °C overnight in a thermocycler with a 70-°C heated lid to limit evaporation. After hybridization, samples were processed using the nCounter PrepStation and Digital Analyzer as per the manufacturer's instructions. nCounter data analysis. Digital counts from barcodes corresponding to protein probes were analyzed as follows: raw counts were first normalized with internal spike-in controls to account for system variation. IgG control counts from each ROI were subtracted to control for nonspecific antibody binding, and values were then normalized by the ultraviolet-light mask area. Average count density weighted by area of tissue assayed was calculated for the CD45 + mask for each tissue.
DNA extraction. Sections from paraffin-embedded tissue or frozen tissues embedded in OCT were reviewed for pathologic diagnosis and dissected if necessary to ensure that ≥ 90% of the sample represented the tumor. Total cellular DNA was isolated from FFPE tissue sections using the QIAmp FFPE DNA isolation kit according to the manufacturer's protocol (QIAGEN Inc) following deparaffinization and proteinase K treatment. The DNeasy blood and tissue kit was used for DNA isolation from frozen tissue according to the manufacturer's protocol (QIAGEN Inc). Whole-exome sequencing data processing. Raw output of the Illumina wholeexome sequencing data was processed using Illumina's Consensus Assessment of Sequence And Variation (CASAVA) tool (v.1.8.2; http://support.illumina.com/ sequencing/sequencing_software/casava.html) for demultiplexing and conversion to FASTQ format. The FASTQ files were aligned to the human reference genome (hg19) using BWA (v.0.7.5) 22 with three mismatches (two mismatches must be in the first 40 seed regions) for a 76-base sequencing run. The aligned BAM files were then subjected to mark duplication, realignment and base recalibration using Picard (v.1.112) and GATK (v.3.1-1) software tools 23 . The generated BAM files were then used for downstream analysis. A genotyping quality check was performed to rule out any possible sample swapping or contamination. In brief, germline single-nucleotide polymorphisms were called using Platypus (v.0.8.1) 24 . Samples from the same patient were confirmed/identified by the percentage of genotypingidentity between them, which was defined by the fraction of identical germline alleles among the overlapping single-nucleotide polymorphisms between the two samples. All samples in this study passed quality check, and no sample swapping or contamination was detected.
Somatic mutation calling, filtering and functional annotations. MuTect (v1.1.4) 25 was applied to identify somatic point mutations, and Pindel (v.0.2.4) 26 was applied to identify small insertion and deletions (indels). The MuTect and Pindel outputs were then run through our pipeline for filtering and annotation. In brief, only MuTect calls marked as 'KEEP' were selected and taken into the next step. For both substitutions and indels, mutations with a low variant allelic fraction (VAF < 0.02) or that had a low total read coverage (< 20 reads for tumor samples; < 10 reads for germline samples) were removed. In addition, indels that had an immediate repeat region within 25 bp downstream towards the 3′ region were also removed. After that, common variants reported by ExAc (the Exome Aggregation Consortium, http://exac.broadinstitute.org), Phase-3 1000 Genome Project (http:// phase3browser.1000genomes.org/Homo_sapiens/Info/Index) or the NHLBI GO Exome Sequencing Project (ESP6500, http://evs.gs.washington.edu/EVS/) with a minor allele frequency greater than 0.5% were removed. The intronic mutations, mutations at 3′ or 5′ untranslated region or regions flanking the untranslated regions, silent mutations and in-frame small indels were also removed.
Mutation load calculation. The mutation load was calculated by counting the total number of somatic nonsynonymous mutations identified in each sample.
T cell receptor sequencing. T cell receptor beta chain CDR3 regions were sequenced by ImmunoSeq (Adaptive Biotechnologies), with primers annealing to V and J segments, resulting in amplification of rearranged VDJ segments from each cell. Clonality and richness values were obtained through the ImmunoSeq Analyzer software. Clonality was measured as 1 − (entropy)/log 2 (number of productive unique sequences), with entropy taking into account clone frequency. Differential abundance analysis was assessed using a modification of the DESeq R package, as previously described 21 , to identify clones that were significantly expanded or contracted from baseline to on-treatment timepoints. Morisita Overlap is a population overlap metric relating the dispersion of clones in the samples and was calculated through the ImmunoSeq Analyzer software. Significantly expanded clones from baseline to on-treatment were identified from the peripheral blood and then compared to clones in baseline tumor sample as well as on-treatment tumor sample to determine expansion of tumorrestricted T cell clones.
Statistical methods.
A total of 20 patients in each arm were planned for enrollment (though 12 patients were randomized to nivolumab monotherapy and 11 patients were randomized to combined therapy with ipilimumab and nivolumab due to early trial closure). We assumed the pCR rate would be 5% for patients in arm A and 15% for arm B, based on extrapolation from RECIST complete response rates in published studies 7, 27, 28 , which corresponds to the prior probability of 0.64 for at least 1 out of 20 patients experiencing the primary outcome event in arm A and 0.96 for arm B. Bayesian analyses for posterior probabilities of response used a prior beta distribution of (0.5, 0.5) ( Supplementary Table 11 ).
Although the primary focus of the clinical trial was the assessment of the two treatment arms separately, statistical comparisons between both arms, and by response status, were performed to inform future studies. Associations between categorical measures and treatment arms were evaluated using Fisher's exact test, whereas differences in continuous measures between treatment arms were tested using the Mann-Whitney U-test. PFS, RFS, DMFS and overall survival were estimated using the Kaplan-Meier method and differences between groups were assessed using the log-rank test. Patients who were alive as of the data cut-off (9 May 2018) were censored in the overall survival evaluation at the date of last contact, whereas those who were alive and had not developed an event as defined in each end point as of the data cut-off were censored in the PFS, RFS and DMFS assessment. Clinical analyses were performed using SAS 9.4 for Windows whereas the biospecimen analyses were performed using GraphPad Prism 7. All statistical tests used an alpha value of 0.05 and were two-sided. 
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